GETINGE GROUP

Carnegie Nordic Health Care Seminar

Johan Malmquist, CEO

24 March, 2010

A rapidly expanding medical technology company

Medical Systems















GETINGE GROUP

A rapidly expanding medical technology company



1993

Getinge AB is listed on the Stockholm Stock Exchange 1996

Acquisition of the american company MDT



2003

Acquisition of Siemens LSS & Jostra

2008

Acquisition of Boston Scientific CS/VS divisions

1989

Carl Bennet & Rune Andersson acquires Getinge 1995

Getinge acquires the Arjo Group





2000

Getinge acquires 4 companies, including MAQUET

MAQUET

2007

Acquisition of Huntleigh Technology PLC

Huntleigh

2009

Acquisition of Datascope




Infection Control

Extended Care

Medical Systems

Continuous growth 1993 – 2009



CAGR Revenue: 22 %


CAGR Profit before tax: 21 %

CAGR Organic growth: 6 - 7 %


Getinge Group 2009

Revenue: SEK 23 billion

Associates: 12 100



Revenue by Business Area



Revenue by division in Medical Systems









STRATEGIC DIRECTION

Well positioned

Getinge has gained a competitive position in its markets that will be further strengthened by current trends:

- Market testing/privatization
- Activity based reimbursement
- Focus on core competencies





Getinge has built a competitive business supported by a robust strategy:

Global leadership

We strive to be a global No 1 or No 2 in the product areas focused. Market leadership will help us attain cost leadership through scale.

Solution provider

We strive to combine the strength of our leading product positions and the depth of our know-how to offer innovative solutions that lead to process improvements for our customers.

Customer relationships

A direct approach to our customers is crucial to our success. Getinge will strive to establish own distribution channels whenever justifiable.

Strategic direction

Global leadership Integrated solutions Sterilization no 1 Integrated Infection Control Disinfection no 1 solutions **Patient Handling** no 1 **Hygiene Systems** no 1 Integrated solutions **Wound Care/TS** no 2 for health care ergonomics IPC / DVT no 1 **Surgical Tables** no 1 **Integrated solutions Surgical Lights** no 1 for surgical **Ceiling Pendants** no 2 procedures **FVH** no 1 **Integrated solutions Beating heart surgery** no 2 for cardiac and **Anastomosis CABG** no 1 vascular surgery Vascular grafts AAA, TAA no 1 **Cardiac Assist IABP** no 1 Integrated Ventilation no 1 solutions for critical care **Anaesthesia**

NEW FINANCIAL TARGETS AND HOW WE REACH THEM

Getinge Group financial targets

- Pre-tax earnings: Average growth of 15% per year
- Long-term organic revenue growth: 5% (next 3-5 years 2% above market, i.e 7%)
- EBITA margin: ~ 20% (MS: 22%, EC: 19%, IC: 16%)
- Cash conversion: 60-70% of EBITDA







We expect to outgrow the markets we serve by 2 % over the next 3-5 years

- Revenue synergies from recent major acquisitions
- R&D investments in recent years have significantly increased our available markets
- We will continue to invest in proprietary sales channels in emerging economies







We expect EBITA margins to continue to improve in future years

- The acquisitions of Huntleigh, Datascope and the Cardiac and Vascular surgery divisions of Boston Scientific represents SEK 600 – 700 M in annual cost synergies
- New and pending product introductions are associated with higher gross margins
- Faster growing recurring revenue base
- Significant scope for further cost improvements in our supply chain



EXTERNAL GROWTH

External Growth

Reinforcing existing leadership positions

• We expect bolt-on acquisitions to add approximately. 2% growth per year.

Focus:

New technology and geographic expansion

Strengthening our capabilities as a solution provider

• We expect acquisitions of new and leading product lines that will strengthen our capcities as a solution provider to add 6-8% growth per year.

Focus:

Increased exposure to therapeutic devices and recurring revenue streams, build on *Surgical Workplaces* platform, broaden *Cardiovascular* franchise.



OUTLOOK 2010

Outlook 2010

- We expect good improvements in organic revenue growth
 - Improving demand situation in USA and emerging markets
 - Stable or somewhat declining demand situation in Europe
- Continued good growth in pre-tax profit
- Restructuring costs will drop significantly in 2010
- Earnings will benefit from favorable currency hedges



A different Getinge

Getinge Recent structural changes have improved our earnings quality

- Enhanced exposure to therapeutic disciplines
- Reduced dependence on capital equipment sales
- Systematic investments in the Group's sales organisation in emerging economies









QUESTIONS & ANSWERS